{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:21:00Z","timestamp":1789791660788,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K06743"],"award-info":[{"award-number":["JP22K06743"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jiac.2023.09.006","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T04:35:53Z","timestamp":1694234153000},"page":"77-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Nirmatrelvir\/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7904-7132","authenticated-orcid":false,"given":"Hideo","family":"Shiohira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-2704","authenticated-orcid":false,"given":"Shingo","family":"Arakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-1676","authenticated-orcid":false,"given":"Kazuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0754-410X","authenticated-orcid":false,"given":"Katsunori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2023.09.006_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and Nirmatrelvir-Ritonavir: oral coronavirus disease 2019 antiviral drugs","volume":"76","author":"Saravolatz","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.09.006_bib2","series-title":"PaxlovidPACK interview form","year":"2023"},{"key":"10.1016\/j.jiac.2023.09.006_bib3","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jiac.2023.09.006_bib4","doi-asserted-by":"crossref","first-page":"18422","DOI":"10.1073\/pnas.1010693107","article-title":"Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir","volume":"107","author":"Sevrioukova","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jiac.2023.09.006_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with Nirmatrelvir\/Ritonavir in patients with COVID-19","volume":"45","author":"Lemaitre","year":"2023","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2023.09.006_bib6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.04.006","article-title":"An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients","volume":"112","author":"Masuda","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jiac.2023.09.006_bib7","doi-asserted-by":"crossref","first-page":"ofac238","DOI":"10.1093\/ofid\/ofac238","article-title":"Supratherapeutic tacrolimus concentrations with Nirmatrelvir\/Ritonavir in solid organ transplant recipients requiring hospitalization: a case series using rifampin for reversal","volume":"9","author":"Rose","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2023.09.006_bib8","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.transproceed.2022.04.015","article-title":"Paxlovid (Nirmatelvir\/Ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report","volume":"54","author":"Prikis","year":"2022","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jiac.2023.09.006_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40780-023-00280-3","article-title":"A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir\/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis","volume":"9","author":"Tsuzawa","year":"2023","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.jiac.2023.09.006_bib10","article-title":"Monitoring tacrolimus toxicity following Paxlovid administration in a liver transplant patient","volume":"36","author":"Maynard","year":"2023","journal-title":"Pract Lab Med"},{"key":"10.1016\/j.jiac.2023.09.006_bib11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00204-008-0332-8","article-title":"Inhibition and induction of human cytochrome P450 enzymes: current status","volume":"82","author":"Pelkonen","year":"2008","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jiac.2023.09.006_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pharmthera.2009.10.011","article-title":"Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information","volume":"125","author":"Hisaka","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jiac.2023.09.006_bib13","series-title":"Fact sheet for healthcare providers: emergency use authorization for Paxlovid","year":"2023"},{"key":"10.1016\/j.jiac.2023.09.006_bib14","series-title":"Paxlovid European public assessment report (EPAR)","year":"2022"},{"key":"10.1016\/j.jiac.2023.09.006_bib15","article-title":"Management of nirmatrelvir\/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series","author":"Guzm\u00e1n Cordero","year":"2022","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.jiac.2023.09.006_bib16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/ajt.16997","article-title":"Effect of nirmatrelvir\/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients","volume":"22","author":"Wang","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jiac.2023.09.006_bib17","first-page":"41","article-title":"Increased plasma tacrolimus concentration after single intravenous administration of voriconazole: a case of drug-drug interaction","volume":"33","author":"Shiohira","year":"2014","journal-title":"Ryukyu Med J"},{"key":"10.1016\/j.jiac.2023.09.006_bib18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3390\/ijms20102413","article-title":"Impact of CYP3A5, POR, and CYP2C19 polymorphisms on trough concentration to dose ratio of tacrolimus in allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Suetsugu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiac.2023.09.006_bib19","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","volume":"23","author":"Loos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiac.2023.09.006_bib20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/j.1552-4604.1993.tb04712.x","article-title":"Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion","volume":"33","author":"Jain","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2023.09.006_bib21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2023.09.006_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2133\/dmpk.21.122","article-title":"Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient","volume":"21","author":"Fukatsu","year":"2006","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jiac.2023.09.006_bib23","doi-asserted-by":"crossref","first-page":"586","DOI":"10.6002\/ect.2012.0032","article-title":"Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients","volume":"10","author":"Nasiri-Toosi","year":"2012","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.jiac.2023.09.006_bib24","first-page":"279","article-title":"Clinical pharmacokinetics of tacrolimus in Iranian liver transplant recipients","volume":"13","author":"Nasiri-Toosi","year":"2014","journal-title":"Iran J Pharm Res (IJPR)"},{"key":"10.1016\/j.jiac.2023.09.006_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23002118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23002118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:06:58Z","timestamp":1761160018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X23002118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1341321X23002118"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2023.09.006","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nirmatrelvir\/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2023.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}